MICA and ovarian cancer: In hematological malignancies and solid tumors, MICA or MICB is expressed in 100% of colorectal tumors, 97% of breast cancers, 95% of renal cell carcinomas, 81% of ovarian cancer, 77% of primary cutaneous melanomas, and 50% of primary uveal melanomas (4, 5, 8, 12).